Learn more about
Life Sciences & Health Care
Participants will evaluate key drivers of R&D productivity and identify strategies to consider when improving portfolio resilience and long-term innovation returns.
Host:
Kevin Dondarski, partner, Life Sciences strategy practice, Deloitte Consulting LLP
Presenters:
David Chapman, director, Deloitte UK LLP
Emily May, Life Sciences Research Manager, Deloitte UK LLP
Colin Terry, partner, Deloitte MCS Limited
1 Overview CPE credit | Specialized Knowledge
Key takeaways
In 2025, R&D productivity across the top 20 biopharma companies showed modest improvement, with projected IRR rising to 7.0%; yet, this gain is heavily concentrated in a narrow set of GLP-1/GIP assets. Beneath the headline, underlying productivity remains challenged, raising important questions about the sustainability of current innovation models. We’ll discuss:
- Drivers behind recent R&D productivity trends
- Key cost and value dynamics shaping pipelines
- Strategic priorities to consider when mitigating concentration risk and improve returns
- Practical approaches to consider when translating AI investment into measurable R&D productivity gains
